Key statistics
On Monday, Royalty Pharma PLC (RPD:STU) closed at 25.06, 6.91% above its 52-week low of 23.44, set on Jul 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.04 |
---|---|
High | 25.06 |
Low | 25.04 |
Bid | 25.08 |
Offer | 25.18 |
Previous close | 25.23 |
Average volume | 140.00 |
---|---|
Shares outstanding | 593.46m |
Free float | 384.69m |
P/E (TTM) | 18.45 |
Market cap | 16.47bn USD |
EPS (TTM) | 1.50 USD |
Annual div (ADY) | 0.7617 EUR |
---|---|
Annual div yield (ADY) | 3.04% |
Div ex-date | Aug 16 2024 |
Div pay-date | Sep 13 2024 |
Data delayed at least 15 minutes, as of Oct 07 2024.
More ▼
Announcements
- Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
- Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
- Royalty Pharma Reports Second Quarter 2024 Results
- Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
- Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
- Royalty Pharma Declares Third Quarter 2024 Dividend
- Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
- Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
More ▼